ACM
TNXP icon

Altium Capital Management’s Tonix Pharmaceuticals TNXP Stock Holding History

Altium Capital Management’s Portfolio TNXP Stock Details TNXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-169
Closed -$218K – 91
2023
Q4 		$218K Buy
+169
New +$272K 0.15% 40

Other funds holding TNXP

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Prudential Financial
Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Altium Capital Management's TNXP Position: Q1 2024 in Review

Altium Capital Management sold out of Tonix Pharmaceuticals (TNXP) in Q1 2024, closing a stake of 169 shares — an estimated $218K sold.

Altium Capital Management first reported a position in TNXP in Q4 2023 and held it in 1 quarter. The position peaked at $218K in Q4 2023. 24 funds tracked by Wall St. Rank hold TNXP as of Q1 2024.

  • Altium Capital Management reported no remaining Tonix Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Altium Capital Management sold 169 Tonix Pharmaceuticals shares in Q1 2024, an estimated $218K.
  • Altium Capital Management first reported a position in Tonix Pharmaceuticals in Q4 2023 and held it in 1 quarter.
  • Altium Capital Management's Tonix Pharmaceuticals position peaked at $218K in Q4 2023.
  • 24 funds tracked by Wall St. Rank held Tonix Pharmaceuticals as of Q1 2024.

Based on Altium Capital Management's 13F filing for Q1 2024, filed 15 May 2024.